|
|
Dear Colleagues,
As many of you may know, CTV’s Executives in Residence (XIR) Program aims to connect Columbia technologies and researchers with seasoned industry executives, venture capitalists, and serial entrepreneurs. By doing so, we hope to leverage the deep domain expertise of these individuals to help accelerate the path of promising Columbia technologies toward market success.
 I am excited to welcome two new CTV XIRs: Dr. Wim Sweldens and Dr. Sam Kongsamut. Wim was most recently the President of Alcatel-Lucent’s Wireless Division, where he led the global development and deployment of LTE 4G technology and oversaw the introduction of the award-winning lightRadio small cell portfolio. Earlier in his role as VP of Network Technology, Wim took the company’s Applications Enablement strategy from paper to practice, allowing service providers to open and leverage their networks for the development of new services and applications. As founder and leader of Alcatel-Lucent Ventures, a strategic new business incubator and investment division inside of Bell Labs, Wim managed the lifecycle - from concept to commercialization - for eight ventures, ranging from enterprise and consumer applications to groundbreaking mobile innovations for operators.
Sam Kongsamut has over 20 years of pharmaceutical R&D and business development experience at Hoechst-Roussel, Aventis, and Sanofi-Aventis. Sam managed various-sized groups of scientists in biochemical pharmacology that served multiple project teams in the neuroscience area, and was a member of the CNS Board that managed the CNS project portfolio. He led or worked on a variety of multi-disciplinary drug discovery and development projects covering a range of technologies and therapeutic indications in neuroscience and aging (OCD, anxiety-depression, schizophrenia, Alzheimer's Disease, Parkinson's Disease, sleep disorders, multiple sclerosis, spinal cord injury, stroke, hearing loss, pain, circadian rhythm disorders, urology, musculoskeletal disorders), including being involved with two marketed drugs that are now helping patients. From 2009-2012, Sam was Director of External Innovation at Sanofi-Aventis, using his experience to identify opportunities for collaboration and licensing for broad therapeutic interests within the Aging Unit.
Wim and Sam join our other current XIRs, Sid Dalal (RAND; Xerox; Bellcore/SAIC/Telcordia) and Jerry Korten (Versamed; GE Healthcare).
Wim, Sam, Sid and Jerry will be available to Columbia researchers and students for advice and consultation during their 3-month term at Columbia. If you have a project that you think may benefit from their experience and expertise, please reach out to your CTV licensing officer or to techventures@columbia.edu to arrange a one-on-one meeting.
We will be adding more XIRs with different backgrounds to the team in the months ahead. For more information, please visit our website at http://techventures.columbia.edu/techdev/executives-in-residence.
Sincerely,
Orin Herskowitz
Executive Director, CTV
VP for Intellectual Property & Technology Transfer
|
|
|
Events & Deadlines
What Happens in Vegas DOESN'T Stay in Vegas: CES Panel Discussion
Date: Wednesday, February 13, 2013
Time: 12:00 PM- 1:00 PM
Private Equity & Venture Capital Conference
Date: Friday, February 15, 2013
Time: 8:00 AM- 6:00 PM
Columbia Entrepreneurship Lecture Series
Speaker: Vishal Misra, Silver Lining
Date: Wednesday, March 20, 2013
Time: 12:00 PM- 1:00 PM
|
|
|
|
|
|
|
|
|
